Ref ID: 18694
Author:
A. Varon, MD – Clinician, M. L. S. Chiganer, MD – Clinician, M. Garnica, MD – Clinician, H. Reis, MS – Lab Technician, M. Paixao, MS – Lab Technician, G. Barreiros, MS – Lab Technician, T. Akiti, MS – Lab Technician, S. A. Nouer, MD – Associate Profe
Author address:
Federal Univ. of Rio de Janeiro, Rio de Janeiro, Brazil.
Full conference title:
52nd Annual ICAAC
Date: 9 September 2014
Abstract:
Background: Cross-reactivity of Fusarium species with serum galactomannan antigen test (GMI) has been observed. We sought to evaluate if GMI could help to early diagnose invasive fusariosis and to monitor treatment response.
Methods: Serial GMI testing (≥ 3x/week) has been applied to high-risk hematological patients (pts) since 2008. We reviewed the records and GMI results of all pts with a diagnosis of invasive fusariosis between 2008 and 2011. We looked at two time points related to the positive GMI (≥ 0.5 optical density): date of first clinical manifestation of fusariosis (skin lesions, lung infiltrates or swollen joint) and date of diagnosis (date of positive culture, direct exam or histopathology).
Results: Eleven pts were diagnosed with invasive fusariosis. The median number of GMI tests performed was 6 (range 2 – 17). Two pts had negative GMI: one had only one test performed, 3 days before the first manifestation of fusariosis, and the other had localized fusariosis (arthritis) with multiple negative GMI tests. Nine pts (82%) had at least one positive GMI (median 2, range 1 – 15). The median value of the first positive and peak GMI was 0.640 (range 0.506 – 0.910) and 0.910 (range 0.506 – 6.382), respectively. In 5 of these 9 pts GMI was positive before the first manifestation of fusariosis (median 6 days, range 5 – 12), and in 4 clinical manifestations preceded the first positive GMI (9.5 days, range 6 – 14). In 6 pts GMI was positive before the final diagnosis of fusariosis (median 10 days, range 5 – 17), in 1 it was positive on the same day and in 2 the diagnosis preceded positive GMI by 6 and 13 days, respectively. All 9 pts received antifungal therapy (voriconazole 5, posaconazol 1, voriconazole plus amphotericin B 3) and 4 (44%) were cured. Negativation of GMI occurred in 2 of the 4 pts who cured and in 2 of the 5 who died.
Conclusions: GMI is frequently positive in invasive fusariosis, and becomes positive before diagnosis in most pts. These findings may have important implications for the choice of antifungal therapy in settings with high prevalence of fusariosis and positive GMI.
Abstract Number: M-1690
Conference Poster: y
Conference Year: 2012
Link to conference website: NULL
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a